BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 26826125)

  • 1. A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma.
    Ilyas SI; Yamada D; Hirsova P; Bronk SF; Werneburg NW; Krishnan A; Salim W; Zhang L; Trushina E; Truty MJ; Gores GJ
    J Biol Chem; 2016 Apr; 291(15):8031-47. PubMed ID: 26826125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation.
    Smoot RL; Werneburg NW; Sugihara T; Hernandez MC; Yang L; Mehner C; Graham RP; Bronk SF; Truty MJ; Gores GJ
    J Cell Biochem; 2018 Jan; 119(1):824-836. PubMed ID: 28661054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma.
    Conboy CB; Yonkus JA; Buckarma EH; Mun DG; Werneburg NW; Watkins RD; Alva-Ruiz R; Tomlinson JL; Guo Y; Wang J; O'Brien D; McCabe CE; Jessen E; Graham RP; Buijsman RC; Vu D; de Man J; Ilyas SI; Truty MJ; Borad M; Pandey A; Gores GJ; Smoot RL
    J Hepatol; 2023 Jan; 78(1):142-152. PubMed ID: 36162702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YAP and the Hippo pathway in cholangiocarcinoma.
    Sugihara T; Isomoto H; Gores G; Smoot R
    J Gastroenterol; 2019 Jun; 54(6):485-491. PubMed ID: 30815737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity.
    Sugihara T; Werneburg NW; Hernandez MC; Yang L; Kabashima A; Hirsova P; Yohanathan L; Sosa C; Truty MJ; Vasmatzis G; Gores GJ; Smoot RL
    Mol Cancer Res; 2018 Oct; 16(10):1556-1567. PubMed ID: 29903769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma.
    Kabashima A; Hirsova P; Bronk SF; Hernandez MC; Truty MJ; Ilyas SI; Kaufmann SH; Gores GJ
    J Hepatol; 2018 Jun; 68(6):1228-1238. PubMed ID: 29408314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
    Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein.
    Saikawa S; Kaji K; Nishimura N; Seki K; Sato S; Nakanishi K; Kitagawa K; Kawaratani H; Kitade M; Moriya K; Namisaki T; Mitoro A; Yoshiji H
    Cancer Lett; 2018 Oct; 434():120-129. PubMed ID: 30031758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers.
    Galli GG; Carrara M; Yuan WC; Valdes-Quezada C; Gurung B; Pepe-Mooney B; Zhang T; Geeven G; Gray NS; de Laat W; Calogero RA; Camargo FD
    Mol Cell; 2015 Oct; 60(2):328-37. PubMed ID: 26439301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
    Li X; Tao J; Cigliano A; Sini M; Calderaro J; Azoulay D; Wang C; Liu Y; Jiang L; Evert K; Demartis MI; Ribback S; Utpatel K; Dombrowski F; Evert M; Calvisi DF; Chen X
    Oncotarget; 2015 Apr; 6(12):10102-15. PubMed ID: 25826091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WWC1 and NF2 Prevent the Development of Intrahepatic Cholangiocarcinoma by Regulating YAP/TAZ Activity through LATS in Mice.
    Park J; Kim JS; Nahm JH; Kim SK; Lee DH; Lim DS
    Mol Cells; 2020 May; 43(5):491-499. PubMed ID: 32451369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma.
    Tóth M; Wehling L; Thiess L; Rose F; Schmitt J; Weiler SME; Sticht C; De La Torre C; Rausch M; Albrecht T; Grabe N; Duwe L; Andersen JB; Köhler BC; Springfeld C; Mehrabi A; Kulu Y; Schirmacher P; Roessler S; Goeppert B; Breuhahn K
    BMC Cancer; 2021 Oct; 21(1):1079. PubMed ID: 34615513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YAP is a critical oncogene in human cholangiocarcinoma.
    Pei T; Li Y; Wang J; Wang H; Liang Y; Shi H; Sun B; Yin D; Sun J; Song R; Pan S; Sun Y; Jiang H; Zheng T; Liu L
    Oncotarget; 2015 Jul; 6(19):17206-20. PubMed ID: 26015398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion.
    Kawano S; Kawada MI; Fukushima S; Arai Y; Shibata T; Miyano SW
    Anticancer Res; 2024 Jun; 44(6):2393-2406. PubMed ID: 38821585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.
    Wang Y; Ding X; Wang S; Moser CD; Shaleh HM; Mohamed EA; Chaiteerakij R; Allotey LK; Chen G; Miyabe K; McNulty MS; Ndzengue A; Barr Fritcher EG; Knudson RA; Greipp PT; Clark KJ; Torbenson MS; Kipp BR; Zhou J; Barrett MT; Gustafson MP; Alberts SR; Borad MJ; Roberts LR
    Cancer Lett; 2016 Sep; 380(1):163-73. PubMed ID: 27216979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deregulation of Hippo kinase signalling in human hepatic malignancies.
    Li H; Wolfe A; Septer S; Edwards G; Zhong X; Abdulkarim AB; Ranganathan S; Apte U
    Liver Int; 2012 Jan; 32(1):38-47. PubMed ID: 22098159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis Through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway.
    Ma W; Han C; Zhang J; Song K; Chen W; Kwon H; Wu T
    Hepatology; 2020 Oct; 72(4):1283-1297. PubMed ID: 31990985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Expression of Yes-Associated Protein (YAP) Maintains Putative Cancer Stemness and Is Associated with Poor Prognosis in Intrahepatic Cholangiocarcinoma.
    Sugiura K; Mishima T; Takano S; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takada M; Miyazaki M; Ohtsuka M
    Am J Pathol; 2019 Sep; 189(9):1863-1877. PubMed ID: 31220448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RHOA activity in expanding blastocysts is essential to regulate HIPPO-YAP signaling and to maintain the trophectoderm-specific gene expression program in a ROCK/actin filament-independent manner.
    Marikawa Y; Alarcon VB
    Mol Hum Reprod; 2019 Feb; 25(2):43-60. PubMed ID: 30395288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice.
    Nishio M; Sugimachi K; Goto H; Wang J; Morikawa T; Miyachi Y; Takano Y; Hikasa H; Itoh T; Suzuki SO; Kurihara H; Aishima S; Leask A; Sasaki T; Nakano T; Nishina H; Nishikawa Y; Sekido Y; Nakao K; Shin-Ya K; Mimori K; Suzuki A
    Proc Natl Acad Sci U S A; 2016 Jan; 113(1):E71-80. PubMed ID: 26699479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.